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Amyotrophic lateral sclerosis (ALS) is a predominant motor neuron
disease that irreversibly targets upper and lower motor neurons.
Upper motor neurons carry motor information from the motor cortex
through the brainstem and spinal cord to the lower motor neurons,
which in turn directly signal to the muscles (Brown & Al-Chalabi,phic lateral sclerosis; ALSFRS-R,
d; CNS, central nervous system;
disease; MS, multiple sclerosis.
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erapeutics, https://doi.org/102017). The loss of somatic motor neurons leads to paralysis that culmi-
nates into respiratory failure and death. ALS has a worldwide incidence
estimated at 1.75/100.000 person-years of follow-up (PYFU), 2.03/
100.000 in men and 1.45/100.000 in women (Marin et al., 2017). Het-
erogeneity is identified in ALS incidence, for instance, between North
Europe-North America-New Zealand (pooled standardized incidence
of 1.81/100.000/PYFU), with regard to East Asia (0.83/100.000 PYFU)
or South Asia (0.73/100.000/PYFU). Moreover, there is variation with
age (characterized by a progressively increased incidence from the
40s, with a peak in the 60s–70s, followed by a sharp decrease) and
with a consistency of age-specific incidence that varies within different
subcontinents (Marin et al., 2018).
In themajority of cases, ALS occurs as a sporadic form,while approx-
imately 10–% of patients suffer from a familial disease attributed toer the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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fied, which are responsible for approximately 60% of familial forms
and 10% of sporadic forms. The most common genetic mutations
known to cause ALS are located in the following genes: C9ORF72 (40%
of familial cases, 5–10% of sporadic), SOD1 encoding superoxide dismut-
ase 1 (20% of familial cases and 2% of sporadic cases), fused in sarcoma/
translated in liposarcoma (FUS, also known as TLS, 5% of familial cases,
1% of sporadic cases) and TARDBP (5% of familial cases, 1% of sporadic
cases). Significant advances were recently made in the molecular com-
prehension of the etiopathogenesis of the disease, although the whole
process of motor neuron death and motor impairment remains a
major challenge in ALS.
In addition to excitotoxicity, the first identified abnormality, the ALS
mechanisms include oxidative stress, metabolism impairment, protein
misfolding and aggregation, cytoskeletal disorganization and defective
axonal transport, reduced nucleocytoplasmic trafficking, endoplasmic
reticulum stress and compromised autophagy, impaired RNA metabo-
lism, and miRNA dysregulation (Taylor, Brown, & Cleveland, 2016).
Most importantly, these pathogenic events occur not only inmotor neu-
rons and their glial partners but also in multiple tissues and cell types
comprising the immune and muscle cells, thus justifying the multisys-
tem and non-cell-autonomous nature of the disease (Chen et al.,
2018); (Hardiman et al., 2017). Regrettably, the pathological derange-
ment of the cross-talk between neuronal and non-neuronal cells is in-
completely understood, and this might be one possible explanation for
therapeutic failures (Serio & Patani, 2018). Recently, cortical hyperexcit-
ability and decreased intracortical inhibition have been considered as
contributory to the disease (Van den Bos et al., 2018). Indeed, hyperex-
citability in the motor cortex, even in the absence of clinical weakness,
induces trans-synaptic motor neuron degeneration in the anterior
horns of the spinal cord through anterograde glutamate-mediated
excitotoxicity (Mills & Nithi, 1997). In addition, decreased intracortical
GABA inhibition has also been identified, further rendering motor cor-
tex neurons hyperexcitable and susceptible to death in ALS (Medelin
et al., 2016). However, these paradigms are not sufficient to explain
the complexity of upper and lower motor neuron degeneration, and
the emerging general explanation is that a convergence of multiple
pathological events is responsible for the onset and progression of the
disease.
Among these events, an unbalance within the wide range of in-
ducers, sensors, and mediators that form the regulatory network of a
neuroinflammatory process contributes to motor neuron degeneration
in ALS. Inducers initiate the inflammatory response by activating spe-
cialized sensors, which in turn stimulate the production of specific
sets of mediators. The inflammatorymediators then alter the functional
state of the target cells, themotor neuronswithin themotor cortex, and
ventral horns of the spinal cord in ALS, in a way that should allow an
adaptive process. However, in the absence of adaptation and resolution
of the inflammatory process, this regulatory network generates an inva-
sive cycle of degeneration that in ALS culminates with motor neuron
loss. Thus, inflammation constitutes another important mechanism
that can tip the balance between protection and neuronal loss, and the
expression of a pro-inflammatory phenotype by microglia plays a cen-
tral role in this process (Liu & Wang, 2017).
Microglia are generally found to accumulate at sites of cellular dam-
age, with the main task of scavenging dead cells and secreting neuron
survival factors. However, inappropriate prolonged activation of mi-
croglia can cause unbalanced responses, further leading to CNS injury
and motor neuron death (Lall & Baloh, 2017). It was proposed that mi-
croglia in ALS are often primed by former pathological insults, genetic
predisposition, or environmental stressors to respond more vigorously
to a subsequent inflammatory stimulation. Thus, inflammatory microg-
lia contribute to boosting and propagating the neurodegenerative pro-
cess, with the cooperation of astrocytes and peripheral immune
signaling to the CNS by mast cells and infiltrated monocytes/macro-
phages (Lam et al., 2016; Trias et al., 2017) but with the contrastingPlease cite this article as: C. Volonté, S. Apolloni and M. Sabatelli, Histami
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Simpson, & Appel, 2018). The elucidation of the signaling pathways
that induce hyperactivation of microglia highly contributes to shed
light on the complex cellular and molecular regulatory networks of
ALS pathology.
Among the constitutively bioactivemolecules with recognized regu-
latory roles in neurotransmission and immune responses in the CNS, the
endogenous biogenic amine histamine (HA), the prototype molecule
mediating peripheral allergic reactions, is well known to induce activa-
tion ofmicroglia and to regulate critical functions including chemotaxis,
phagocytosis, and cytokine secretion in vitro and in vivo.
With focus on the documented impact of HA on conditioning the in-
flammatory profile of microglia (Thonhoff et al., 2018), the aim of this
review is to gather the most recent information and discuss about the
emerging role that HA might assume in ALS pathogenesis. We propose
that the histaminergic modulation might become a candidate mecha-
nism for understanding ALS insurgence, progression, and therapy. The
idea that histaminergic drugs might be proven to work also in ALS
could appear either provocative or appealing but surely deserving
deeper scientific consideration.
2. Current therapeutic strategies in ALS
ALS is a relentless disease typically causing death within 3–5 years
from the onset. Despite decades of extensive research and randomized
controlled clinical trials, almost all efforts aimed at identifying a success-
ful treatment regimen have failed thus far. Genetic heterogeneity, diag-
nostic delay, poor clinical trial design or rationale, insufficient
animal models, and lack of reliable biomarkers are among the potential
reasons limiting significant development in clinical trials (Katyal &
Govindarajan, 2017). Presently, there are only two FDA-certified
drugs: i) riluzole (Rilutek®, Teglutik®, approved back in 1995), an
anti-glutamatergic drug that has shown to prolong survival at most by
2–3months; ii) edaravone (Radicava®, Radicut®), whichwas approved
in Japan in 2015 and in the USA in 2017 based on a modest, although
statistically significant, result of randomized controlled clinical trials
performed with patients at early-stage ALS. However and regrettably,
none of these drugs are fully satisfactory, and new ideas are mandatory
for supporting further studies and formulating more effective
treatments.
2.1. Approved drug edaravone
Edaravone is the first new drug approved by the FDA for the treat-
ment of ALS sincemany years. It is reported to confer protection against
oxidative stress through its electron-donating properties, based on
studies performed both in vitro and in vivo on neuron, glial, and vascular
endothelial cells (Takei et al., 2017). Although the mechanisms by
which edaravone might be effective were unknown during its approval
and also currently, the edaravone clinical program was developed as a
multistudy series spanning 16-plus years and involving randomized
clinical trials, extension trials, and post hoc analysis, with the final goal
of providing effective treatments to ALS patients. The study MCI 186-
19 was the culmination of a 13-year edaravone clinical development
program. In particular, in a randomized controlled study, a total of 137
patients were recruited, 69 in the edaravone and 68 in the placebo
group. The results showed that the mean change in ALSFRS-R scores
for the edaravone group was −5.01 ± 0.64 compared with that of
−7.50± 0.66 for the placebo group. There was a statistically significant
least-squaresmeandifference in ALSFRS-R scores between the 2 groups,
representing 33% less functional loss in patients treated with edaravone
than those who received placebo during the course of 24 weeks. The
benefits and safety of edaravone in the treatment of ALS were then re-
evaluated in a recent meta-analysis study demonstrating that intrave-
nous edaravone is efficacious in ALS patients with no severe adverse ef-
fects (Luo, Song, Li, Huiwang, et al., 2019). Notwithstanding thesene beyond its effects on allergy: Potential therapeutic benefits for the
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larger sample sizes will further assess the efficacy and safety of
edaravone in ALS.
2.2. New drugs under trial
N50 clinical trials with potential ALS drugs have failed thus far, and
there is a continuous intense search for treatments (Table 1). Here, we
provide a brief description of only those compounds currently in inter-
ventional clinical trials of phase-III and independently from the recruit-
ment status of the trials.
Tauroursodeoxycholic acid (TUDCA) is a unique bile acid derivative
that acts as a potent antiapoptotic agent. TUDCA has been shown to re-
store the function of motor neurons by stabilizing the mitochondrial
membrane, inhibiting nitrite production, and preventing the activation
of matrix metallopeptidase 9 (Vaz et al., 2015). The neuroprotective ef-
fects of this compound are confirmed in human stemcell-derivedmotor
neurons carrying a mutated SOD1 allele. Moreover, the administration
of TUDCA in SOD1-G93A mice reduces muscle denervation (Thams
et al., 2019). In addition to the SOD1-G93A model, TUDCA has shown
promising effects also in the C9ORF72 model by providing protection
against poly(GA)-induced toxicity, a pathogenic mechanism implicated
in the neurodegenerative processes of C9FTD/ALS (Zhang et al., 2014).
In patients, a pilot study has provided preliminary clinical data indi-
cating that TUDCA is safe and may be effective in slowing ALS progres-
sion (Elia et al., 2016). TUDCA is currently under investigation in a
Phase-III clinical trial for ALS patients.
Methylcobalamin is a vitamin B12 analog that effectively and dose
dependently prevents embryonic stem cell-derived motor neuron
death induced by co-culturing conditions with SOD1-G93A astrocytes.
Moreover, treatment with methylcobalamin together with the conven-
tional ALS drug riluzole further enhances survival of motor neurons in
this in vitro ALS system (Ito, Izumi, Niidome, & Ono, 2017). In the wob-
bler mouse characterized by cellular transport defects, neurofilament
aggregation, neuronal hyperexcitability, and neuroinflammation, thus
showing striking similarities to ALS, methylcobalamin at a very high
dose of 30 mg/kg significantly inhibits denervation muscle atrophy
and motor axonal loss by attenuating motor symptoms (Ikeda,
Iwasaki, & Kaji, 2015). In patients with ALS, previous reports have sug-
gested that administration of high-dose methylcobalamin could have
clinically beneficial effects (Izumi & Kaji, 2007). Moreover, the results
of a recent study have shown that although an ultra-high dose of
methylcobalamin has not demonstrated significant efficacy in patients
with ALS, the treatment may prolong survival and delay disease pro-
gression if started early (≤12 months of duration) (Kaji et al., 2019).
Methylcobalamin is currently under investigation in a Phase-III clinical
trial for patients with ALS.
Masitinib is a type-3 tyrosine kinase inhibitor known to modulate
neuroinflammatory features associated with many neurodegenerative
disorders. In microglia cultures from symptomatic SOD1-G93A spinalTable 1
Ongoing Phase-III interventional trials on ALS.
Compound Target/mechanism Recruiting Identifier
Tauroursodeoxycholic
acid
Anti-apoptotic Not yet NCT03800524
Methylcobalamin B12 vitamin derivative Yes NCT03548311
Masitinib Tyrosine kinase c-Kit
inhibitor
Not yet NCT03127267
CannTrust CBD Oil Active cannabinoid Yes NCT03690791
Arimoclomol Stimulates repair pathways Yes NCT03491462
Levosimendan Calcium channel sensitizer Yes NCT03505021
Deferiprone Iron chelator Not yet NCT03293069
MSC-NTF cells Mesenchymal cell therapy Yes NCT03280056
Search query: ALS (Amyotrophic Lateral Sclerosis) https://clinicaltrials.gov/ Filtered for:
Status: Recruiting – Not yet recruiting – Active, not recruiting – Enrolling by invitation;
Study type: Interventional (Clinical Trial); Study Phase: Phase-III.
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proliferation, cell migration, and the expression of inflammatory medi-
ators. Treatment with masitinib started after the onset of paralysis in
SOD1-G93A rat prolongs post-paralysis survival and decreases the
number of aberrant glial cells, microgliosis, and motor neuron pathol-
ogy in the spinal cord (Trias et al., 2016). Moreover, masitinib prevents
the excessive accumulation of mast cells in the skeletal muscles of
symptomatic SOD1-G93A rats and delays neuromuscular junction de-
nervation (Trias et al., 2017; Trias et al., 2018). Results of phase-II/III tri-
als on patients with ALS have confirmed that the study has met its
primary end point, demonstrating a potential therapeutic benefit for
masitinib (Kiernan, 2018). Masitinib is currently under investigation
in a Phase-III clinical trial for patients with ALS.
Cannabidiol (CBD) is one of the N100 pharmacologically bioactive
compounds defined as cannabinoids that can be isolated from the Can-
nabis sativa plant. Because it does not possess the psychoactive proper-
ties of other cannabis-related compounds, cannabidiol holds a
considerable therapeutic potential. By binding to specific receptors, can-
nabinoids have shown antioxidant, anti-inflammatory, and neuropro-
tective effects in many preclinical models of neurodegenerative
diseases, which include ALS. In many studies on the SOD1-G93A
model, cannabinoids have reported neuroprotective activity, delaying
disease progression and motor impairment and prolonging survival of
the animals. In patients with ALS, studies that aimed at investigating
the effect of cannabinoids have only focused on the alleviation of ALS-
related symptoms, not on the control of disease progression. In a
proof-of-concept trial, nabiximols (a specific extract of Cannabis) has
shown a positive effect on spasticity symptoms in patients with ALS,
with an acceptable safety and tolerability profile (Riva et al., 2019).
Cannabidiol is currently under investigation in a Phase-III clinical trial
for patients with ALS.
Arimoclomol is a hydroxylamine derivative acting as a co-inducer of
heat shock proteins expression that is found effective in delaying dis-
ease progression and extending the lifespan of SOD1-G93A mice even
when administered at the symptomatic phase (Kalmar et al., 2008). In-
deed, pharmacological activation of the heat shock response is consid-
ered a successful therapeutic approach for treating ALS. Enhanced heat
shock proteins expression not only affects protein aggregation but can
also lead tomore effective clearance of protein aggregates, by triggering
the proteasome-ubiquitin system or autophagy responses (Kalmar, Lu,
& Greensmith, 2014). Not surprisingly, arimoclomol-treated SOD1-
G93A mice have shown a clear improvement of muscle function and
motor neuron survival (Kieran et al., 2004), together with a decrease
in the number of ubiquitin-positive aggregates in the spinal cord, and
an improvement in neuromuscular function (Kalmar, Edet-Amana, &
Greensmith, 2012). In patients with ALS, arimoclomol has shown good
safety record (up to 300 mg/day) for a short period of time
(12 weeks) and a good penetration across the blood–brain barrier
(Cudkowicz et al., 2008). A Phase-II study has clearly shown that
arimoclomol is safe and well tolerated at a dosage of 200 mg three
times a day for up to 12 months. Although not powered for therapeutic
effect, the results of this study suggest a perspective therapeutic benefit
of arimoclomol (Benatar et al., 2018). Arimoclomol is currently under
investigation in a Phase-III clinical trial for ALS patients.
In addition to these studies, additional and innovative approaches
are currently tested for treating ALS, as, for instance, the use of gene si-
lencing in cases where a genetic cause of ALS is identified and the corre-
sponding transcript or protein is assumed to exert toxic activities. In
particular, the strategies trying to suppress or alleviate the toxic actions
of etiologic ALS genes include targeted ablation of the defective gene
transcript by antisense oligonucleotides or microRNA, DNA mutagene-
sis reverting the defective gene to its wild-type form in the appropriate
non-germline cells, interference with the transcriptional process by the
use of small molecules, immune-mediated neutralization of themutant
protein, andmesenchymal stromal cells as an autologous stem cell ther-
apy. Clinical trials investigating the use of antisense oligonucleotides tone beyond its effects on allergy: Potential therapeutic benefits for the
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and the positive results from an interim analysis of Phase-I clinical
trial with antisense oligonucleotide for treating ALS caused by SOD1
mutations (unpublished data) provide hope for opening a new era in
the treatment of ALS.
Several treatments that are not discussed in this work are presently
under scrutiny in clinical trials of Phase-I/II: for details, please refer to
https://clinicaltrials.gov/.
3. Pleiotropic actions and signaling of histamine in the CNS
HA has been a milestone in pharmacology and immunology since
1910 when Sir Henry Dale and Patrick Laidlaw identified its potent
physiological actions (Dale & Laidlaw, 1910). TheNobel Prize in Physiol-
ogy and Medicine was then awarded twice for HA-related drugs, in
1957 to Daniel Bovet for the discovery of antihistamines (anti-H1R)
and in 1988 to Sir James Black for the discovery of anti-H2R antagonists.
While H1R, H2R, and H4R antagonists have revolutionized the available
therapies for allergic, gastric, and immune disorders, H3R antagonists
have more recently entered clinical trials for applications in obesity
and a large variety of neurological disorders (Cataldi, Borriello,
Granata, Annunziato, & Marone, 2014; Ghamari et al., 2019).
Given the large array of biological functions directly regulated byHA
that furthermore is mirrored by the widespread projections of hista-
minergic neurons in the brain,we expect that the targets for HA therapy
might even increase in the near future.
3.1. Histamine metabolism and physiology
In eukaryotic cells, the rate of HA synthesis is determined by the bio-
availability of L-histidine that is taken up by the cells through the L-
amino acid transporter system. HA is synthesized exclusively by decar-
boxylation of L-histidine by histidine decarboxylase (HDC). Once
synthetized inside the cells, the vesicular monoamine transporter
VMAT-2 is then responsible for the internalization of HA into vesicles.
HA is then secreted in the microenvironment by exocytosis, upon
stimulation, and is catabolized by the extracellular enzymes HA
N-methyltransferase (HNMT) or diamine oxidase (DAO). The enzymes
responsible for the transport andmetabolism of HA are ubiquitous pro-
teins in the nervous system.
In the CNS, the sources of HA include mast cells, neurons, and mi-
croglia (Katoh et al., 2001), while peripherally, HA is produced and se-
creted by basophils, neutrophils, monocytes, macrophages, dendritic
cells, platelets, enterochromaffin-like cells, and gastrin-containing
cells. HA neurotransmission follows the circadian rhythm, and HA is re-
leased throughout the brain with a daily rhythm characterized by peak
release during wakefulness and relatively lower levels during sleep.
Most of HA release is nonsynaptic, thus implying a wide diffusion
through a concentration gradient. A nonsynaptic diffusion of HA is fur-
thermore consistent with the features of the selective metabotropic re-
ceptors for HA, H1R-H4R, which act through “slow” transmission
mechanisms requiring the production of intracellular second messen-
gers. Combined with an abundant expression of H1R-H4R receptors,
this suggests a profuse and widespread histaminergic control of neural
circuit activity (Bolam & Ellender, 2016).
H1R-H4R receptors are differentially expressed in the CNS by immu-
nocompetent cells, neurons, astrocytes, microglia, and endothelial cells.
The downstream pathways triggered after binding of HA comprise the
activation of G-proteins (Gαq/11, Gsα, and Gαi/o) and phospholipase
C, leading to inositol triphosphate-dependent release of calcium from
intracellular stores and diacylglycerol formation with modulation of
voltage-dependent calcium channels. Activation of adenylyl cyclase
and stimulation of phospholipase A2 with arachidonic acid production
also occur, with activation of kinases, among which mitogen-activated
protein kinases, protein kinase B, glycogen synthase kinase 3, protein ki-
nase A, AMP-kinase. Cyclic AMP-dependent response element-bindingPlease cite this article as: C. Volonté, S. Apolloni and M. Sabatelli, Histami
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tric oxide and cyclic GMP through nitric oxide-dependent guanylyl cy-
clase. Through these mechanisms, HA triggers several distinct
responses in the target cells culminating in early and late gene expres-
sion modulation and control of several physiopathological functions.
H1R-H3R are the receptors most expressed in the brain, whereas
H4R ismainly present peripherally on immune cellsmodulating neutro-
phil release, eosinophil shape, and mast cell chemotaxis during an in-
flammatory insult (Thurmond, 2015). In the CNS, H1R activation is
linked to excitatory stimulation, responsible for controlling nutritional
state and wake–sleep cycles, and, moreover, found involved in
neuroinflammatory processes (Fukui et al., 2017). Mutant mice lacking
the H1 receptor show defective locomotor and exploratory behaviors
(Parmentier et al., 2016; Yanai et al., 1998). H2R regulates gastrointesti-
nal secretion,muscle relaxation, vasodilation, and neutrophil activation,
playing a role in neuronal plasticity, hippocampal synaptic transmis-
sion, and cognitive performance (Monczor & Fernandez, 2016). H3R is
themost abundant HA receptor in the CNS, expressed by neurons, astro-
cytes, microglia, and oligodendrocyte precursors (Garcia-Galvez, Arias-
Montano, Morales-Figueroa, Nieto-Alamilla, & Marquez-Gomez, 2016;
Haas, Sergeeva, & Selbach, 2008). H3R is involved in cognitive processes,
and activation of this receptor promotes wakefulness (Schlicker &
Kathmann, 2017). Both synthesis and release of HA in the CNS are
under the control of presynaptic H3R located on neuronal soma and ax-
onal varicosities. H3R, moreover, behaves as an autoreceptor by
inhibiting the synthesis and release of HA and also as a heteroreceptor
inhibiting other neurotransmitters such as dopamine, serotonin, nor-
adrenaline, GABA, glutamate, and acetylcholine (Deng, Weston-Green,
& Huang, 2010). Blockade of H3R in the CNS results in increased synthe-
sis and release of HA (Brabant, Charlier, & Tirelli, 2013).
In microglia, the activation of H1R-H4R receptors controls basic
functions such as migration, phagocytosis, and release of cytokines/
chemokines (Barata-Antunes, Cristóvão, Pires, Rocha, & Bernardino,
2017). Accumulating evidence under in vitro and in vivo inflammatory
conditions indicates that HA exerts beneficial effects by stimulating
anti-inflammatory actions in microglia (Apolloni et al., 2017). HA defi-
ciency instead reduces the neuroprotective role of microglia in vivo
and inhibits cell ramifications and expression of IGF-1 through the
H4R (Frick, Rapanelli, Abbasi, Ohtsu, & Pittenger, 2016). In addition,
the HA precursor histidine through H1R, but not H2R, inhibits microglia
activation and IL-1β upregulation in lumbar spinal cord, also alleviating
mechanical allodynia and thermal hyperalgesia after partial sciatic
nerve ligation in rats (Yu et al., 2016). On the other hand, HA triggers
microglial phagocytosis through H1R activation and ROS production
through H1R and H4R activation, and injection of HA in the substantia
nigra of adult mice in vivo induces dopaminergic neurotoxicity through
H1R (Rocha et al., 2016). Activation of H3R instead inhibits chemotaxis
in hippocampal slices and in primary microglia in culture, phagocytosis
in prefrontal cortex, proinflammatory cytokine production, and im-
proves depression-like behavior in the mouse tail suspension test (Iida
et al., 2015; Iida et al., 2017). These results clearly establish a dual role
for HA in microglia, respectively, pro-inflammatory during basal condi-
tions, while anti-inflammatory under inflammatory and pathological
states (Barata-Antunes et al., 2017).
Astrocytes cooperate to neuronal functions through numerous cell-
to-cell interactions and are involved in several neurological disorders.
Recent knowledge has established that HA can influence also some
key astrocytic activities during health and disease conditions, such as
ion homeostasis, energy metabolism, neurotransmitter clearance, neu-
rotrophic activity, and immune response. These processes are mediated
through the HA receptor subtypes, H1R, H2R, and H3R, abundantly
expressed by astrocytes (Jurič, Kržan, & Lipnik-Stangelj, 2016). Negative
regulation of astrocytic TNFα and IL-1β production and the enhance-
ment of astrocytic GDNF are also stimulated by HA as H1R-H3R
receptor-mediated processes (Xu et al., 2018). Moreover, HA activates
human astrocytoma cells signaling through histamine H1R and H2R,ne beyond its effects on allergy: Potential therapeutic benefits for the
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concentration-dependent release of [Ca2+] from internal stores and
concentration-dependent increase in glutamate release. H2R activation
increases cyclic adenosine monophosphate levels and phosphorylation
of transcription factor cAMP response-element binding protein, thus
emphasizing a role for HA in neuron-glia communication (Kárpáti
et al., 2018).
HA neurons are foundmerely in the tuberomamillary nucleus of the
posterior hypothalamus, from where they project their axons all over
the CNS and spinal cord in rats, mice, and humans (Blandina, Munari,
Provensi, & Passani, 2012). Two main bundles of axons from the
tuberomamillary nucleus send a large arborization, for instance, to the
cortex, andmost cortical regions receive amoderately dense and sparse
histaminergic input. Among these regions, the primary motor cortex
(containing giant pyramidal Betz cells or upper motor neurons) is a
key structure that receives abundant histaminergic projections. Upper
motor neurons then send their axons down to the spinal cord through
the corticospinal tract, where in humans, they synapse directly with an-
terior horn cells (the lower motor neurons), which, in turn, synapse di-
rectly with their target muscles. Importantly, HA directly excites rat
spinal motor neurons through H1R and H2R by increasing their excit-
ability, affecting membrane input resistance, and potentiating their re-
petitive firing behavior. In this way, the hypothalamus-spinal cord
histaminergic fibers directly modulate final motor outputs and actively
regulate ongoing motor execution and spinal motor reflexes (Wu et al.,
2012). The elaboration of motor responses into different behavioral
states, motor plans, voluntary movements, and motor skills actually re-
lies on the ability of selecting appropriate motor outcomes according to
specific environmental inputs, and HAwith its receptors actively partic-
ipates to this modulation of motor control. It is now important to recall
and emphasize that both upper and lowermotor neurons are the exclu-
sive targets of neurodegeneration and motor impairment during ALS.
In addition to motor circuits, histaminergic neurons provide a vari-
ety of different signaling mechanisms to the brain. HA directly controls
key functions such as the sleep-wake cycle, aggression, feeding,
nociception, learning, andmemory. Of note, several of the physiological
roles of HA are correlated to its capacity to potentiate the excitability of
most CNS neurons, and for this reason, HA is rightly considered a regu-
lator of “whole brain” activity. In addition to these neuronal effcts, HA
regulates the multidirectional information that maintains a proper bal-
ance between the CNS and peripheral immune functions. Indeed, the
CNS promptly responds to several peripheral inflammatory reactions,
CNS alterations are often translated into peripheral immune changes,
and HA is the master molecule of this neuroimmune regulation
(Cacabelos, Torrellas, Fernández-Novoa, & Aliev, 2016) that, of note,
plays a central role also in ALS.
3.2. Role of histamine in disease pathology
As proven by human post-mortem and animal studies, the HA sys-
tem is highly implicated and becomes altered in the diseased CNS, for
instance, after ischemia; traumatic brain and spinal cord injury;
Alzheimer's (AD), Huntington's (HD), and Parkinson's (PD) diseases;
multiple sclerosis (MS); andWernicke's encephalopathy (for a compre-
hensive review, consult: Hu & Chen, 2017; Ghamari et al., 2019). More-
over, HA deficiency has been directly implicated as a cause of Tourette
syndrome and may contribute to neuropsychiatric conditions compris-
ing schizophrenia, as well as narcolepsy, food intake, and sleep
disorders.
For instance, in cerebral ischemia, a particular value for treatment is
provided by HA able to act on multiple cellular targets. After middle ce-
rebral artery occlusion inducing focal ischemia in the cortex and stria-
tum, the release of HA from histaminergic neurons and from
degranulating mast cells accumulated in the ipsilateral hemisphere
(McKittrick, Lawrence, & Carswell, 2015), gradually increases in both
cortex and striatum (Adachi, Itoh, Oishi, & Saeki, 1992). The expressionPlease cite this article as: C. Volonté, S. Apolloni and M. Sabatelli, Histami
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eral lines of evidence have now shown that HA behaves as long-term
neuroprotectant on neurological score, cognitive ability, and infarct
area reduction after acute ischemia (Liao et al., 2015).
Alterations of the histaminergic transmission are also evident in AD,
where thefirst signs of either increased or decreased HA levels were de-
scribed in the cortex, basal ganglia, hypothalamus, and hippocampus,
together with decreased binding of HA to H1R in the frontal and tempo-
ral areas, which correlated with the severity of symptoms. In addition,
H3R and HNMT are found to be increased in the prefrontal cortex of pa-
tients with AD (Zlomuzica et al., 2016). Remarkably, H3 antagonists
ameliorate cognitive deficiencies in AD transgenic mice, also reversing
the hyperphosphorylation of tau in the spinal cord and hippocampus
(Bardgett, Davis, Schultheis, & Griffith, 2011; Bitner, Markosyan,
Nikkel, & Brioni, 2011). Finally, H3 antagonists prevent neuronal
death (Fu et al., 2010) and promote neurogenesis (Bernardino et al.,
2012), thus suggesting that HA participates in the pathological process
of AD and that HA drugs might be therapeutically effective. Not surpris-
ingly, series of Phase-II clinical studies have been carried out to investi-
gate the efficacy and safety of H3R antagonists to treat cognitive
symptoms in patients with AD. For instance, GSK239512 is a potent
and brain-permeant H3R antagonist in clinical trial for AD (Hu & Chen,
2017).
HD is characterized by motor and nonmotor symptoms for which
there is currently no cure. HA signaling is affected in patients with HD
(Shan, Dauvilliers, & Siegel, 2015). In particular, HDC, HNMT, H1R, and
H3R mRNA levels are increased in the inferior frontal gyrus of patients
with HD, showing a positive correlation of HNMT with CAG repeat
length, and a negative correlation of HNMT and H1R with age at onset
of disease. H2R and H3R are instead decreased in the caudate nucleus
of HD patients, and H3R binding is significantly lower in caudate, puta-
men, and globus pallidus in patients with HD (Van Wamelen et al.,
2011). These findings indicate a functional modulation of histaminergic
signaling in HD brain and provide a rationale for the use of HA receptor
antagonists for therapeutic purposes. Indeed, recent evidence has
established that daily administration of a H3R antagonist/inverse ago-
nist improves nonmotor symptoms including strengthening activity
rhythms, cognitive performance, and mood in the Q175 mouse model
of HD that recapitulates many of the symptoms identified in patients
with HD, including disruptions of the sleep/wake cycle (Whittaker,
Wang, Loh, Cachope, & Colwell, 2017). These results thus establish
that drugs targeting the H3R systemmay show benefits as cognitive en-
hancers in the management of HD.
HA is well known to control motor circuits, and motor symptoms
such as bradykinesia, tremor and gait impairment are key hallmarks of
PD. In particular, the HA system is involved in the basal ganglia
neurocircuitry (Bolam & Ellender, 2016) and HA levels and the number
of histaminergic fibers are augmented in the substantia nigra, putamen,
and globus pallidus of patients with PD. In addition, H3R controlling the
synthesis and release of HA is highly expressed in the striatum and
forms heterodimers with dopamine D1R and D2R receptors, respec-
tively, inhibiting the second messenger cAMP production and lowering
the affinity of dopamine for its receptor. Remarkably, the H3R agonist
immepip mitigates the apomorphine-induced turning behavior in 6-
hydroxydopamine-lesioned rats, and immepip co-administered with
L-DOPA significantly alleviates L-DOPA-induced dyskinesia and chorea.
However, direct injection of immepip in the substantia nigra increases
the turning behavior following systemic apomorphine administration
in rats (Garcia-Galvez et al., 2016). The H3R antagonist thioperamide al-
leviates apomorphine-induced turning behavior in 6-OHDA-lesioned
rats (Nowak et al., 2009) and, finally, the H3R antagonist pitolisant re-
duces the excessive diurnal sleepiness of patients with PD but without
having effects on motor performance (Schwartz, 2011). These are few
among the several lines of evidence suggesting that the histaminergic
and dopaminergic transmissions are closely linked, although additional
studies are needed to fully elucidate the complex role of HA in PD.ne beyond its effects on allergy: Potential therapeutic benefits for the
.1016/j.pharmthera.2019.06.006
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thus playing a central role in the remyelination process occurring after
both acute spinal cord lesions, and chronic demyelinating conditions
of MS (Chen et al., 2017). HA and its receptors are directly implicated
in MS disease pathogenesis, and HA levels are found to be increased in
the cerebrospinal fluid of patients with MS. HA plays a critical role in
ameliorating MS, by reducing the ability of myelin autoreactive T cells
to adhere to inflamed brain vessels, a crucial step in the development
of MS. Most recently, a randomized, single-blind, Phase-II clinical
study on relapsing-remitting multiple sclerosis has demonstrated the
safety, pharmacokinetics, and favorable lesion remyelinating activity
of the H3R antagonist/inverse agonist GSK239512 (Schwartzbach
et al., 2017). Similarly, in the mouse cuprizone/rapamycin model of de-
myelination, the systemic administration of the brain-permeable H3R
antagonist GSK247246 enhances remyelination and subsequently pro-
tects axons (Chen et al., 2017). Finally, the high H3R expression in oligo-
dendroglial cells from patients with MS presenting demyelinating
lesions has validated a genetic association between an exonic single nu-
cleotide polymorphism in H3R and the susceptibility to multiple sclero-
sis (Chen et al., 2017).
Whether released from neurons, microglia, or mast cells, HA partic-
ipates in CNS diseases also by contributing to vascular changes, alter-
ations in the blood–brain barrier, and modulation of immune
functions. The nature of the inflammation, the strength and the resolu-
tion of the responses, and more complex events, for instance, the per-
ception of pain during inflammation are also influenced by HA
(Bañuelos-Cabrera, Valle-Dorado, Aldana, Orozco-Suárez, & Rocha,
2014).
Overall, these results unequivocally demonstrate that both the levels
of HA and the signaling of H1R-H4R in the CNS are strictly controlled
and modulated during several pathological conditions and neurological
disorders. HA seems to exert protective effects in models of acute and
chronic neurodegenerative and neuroinflammatory conditions, to the
point that several different HA drugs, in particular H3R modulators,
are investigated in recent years for their beneficial effects in animal
models of PD, attention-deficit/hyperactivity disorder, schizophrenia,
dementia, and depression (Łażewska & Kieć-Kononowicz, 2018; Hu &
Chen, 2017). This unanticipated knowledge about the several mecha-
nisms that HA is involved with in the CNS clearly suggests that the
field is blooming and that further investigations might even lead to
novel uses of the HA therapeutics currently available.
4. A novel histaminergic perspective in ALS
We have described thus far that HA and its receptors are key regula-
tors of a plethora of biological processes and pathological conditions in
the CNS. Moreover, the development of transgenic mice lacking HA re-
ceptors (Schneider, Neumann, & Seifert, 2014) or unable to synthesize
HA (Ohtsu, 2010), in addition to several preclinical studies, have
shown clear values for several HA drugs that might find widespread
therapeutic applications. Finally, the human variance of HA genes
influencing disease susceptibility, severity, and treatment is prospecting
even further functions for HA that extend well beyond its established
roles. If we now conjugate more than a century of clinical successful in-
vestigations in support of HA drugs (Tiligada & Ennis, 2018), with ap-
proximately 20 years of failures in ALS clinical trials (Petrov,
Mansfield, Moussy, & Hermine, 2017), it appears natural to inquire
whether HA might indeed show a true value also in ALS.
Current research goals in ALS include understanding what causes
motor neuron death; identifying further genes involved in disease
development; validating new biomarkers to aid diagnosis; improving
patient stratification and therapy efforts; and discovering new treat-
ments including drugs, antibodies, and stem cell and gene therapies.
The aim of this chapter is to introduce a novel histaminergic perspective
in ALS by describing how the histaminergic signaling is involved and
might even work against the disease (Fig. 1). Given the large, untappedPlease cite this article as: C. Volonté, S. Apolloni and M. Sabatelli, Histami
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promising time for translational HA research in ALS.4.1. Integrative expression analysis
Recent work has proposed that HA might play a direct role in ALS
(Volonté, Parisi, & Apolloni, 2015). First, H1R-H4R, HDC, HNMT, and
DAO are abundantly and differently distributed in microglia purified
fromSOD1-G93Amice (Apolloni et al., 2017), themost exploited animal
model that recapitulates key ALS features. HA receptors and enzymes
are also expressed in cultured SOD1-G93A primary motor neurons
(Apolloni et al., 2019). Moreover, HA receptors and metabolic enzymes
are present in glia and motor neurons of lumbar spinal cord of symp-
tomatic SOD1-G93A mice and, most importantly, they are found to be
differentially regulated in SOD1-G93A mice during disease progression
(Table 2). For instance, H1R is upregulated in the cortex at the symp-
tomatic and the end stage and downregulated in the lumbar spinal
cord at the presymptomatic and symptomatic phases. H2R is decreased
in the cortex at the symptomatic phase and in the spinal cord at the end
stage. H3R seems not to be modulated during disease progression, and
H4R is increased in cortex at the presymptomatic phase and in the spi-
nal cord at the symptomatic phase. HDC is significantly overexpressed
in the cortex at the symptomatic phase, while it is downregulated in
the spinal cord at the presymptomatic phase but upregulated at the
end stage of the disease. HNMT is augmented in the cortex and spinal
cord at the symptomatic phase. Finally, DAO is not affected during the
disease in the cortex but upregulated in the lumbar spinal cord at the
symptomatic and the end stage (Apolloni et al., 2017).
In addition to the protein expression data obtained from the
SOD1G93A mouse model, whole-genome expression profiles of the
motor cortex and spinal cord were obtained from control subjects and
patients with sporadic ALS (sALS). Several genes involved in themetab-
olism, transport, secretion, and signal transduction pathways of HA are
indeed confirmed to be differentially deregulated in two separate
transcriptome-based subgroups of patients with ALS segregated by un-
supervised hierarchical clustering and termed sALS1 and sALS2
(Aronica et al., 2015). In particular, cortical expression of H1R, HDC,
HNMT, and DAO is increased in sALS2, while H2R and H3R are selec-
tively reduced. H4R is differently modulated in sALS1 (downregulated)
versus sALS2 (upregulated), with regard to healthy individuals. On the
other hand, spinal cord analysis showed deregulation of H1R (reduced)
andH3R (increased) in subgroups sALS1 and sALS2 of patients with ALS
(Table 3) (Apolloni et al., 2017). Despite some intrinsic singularities and
exceptions, in both subgroups of patients with sALS, the HA system
shows substantial upregulation of H1R in the cortex (as in SOD1-G93A
mice) but downregulation in the spinal cord (as in presymptomatic
and symptomatic ALS mice), together with increased expression of
H3R in the spinal cord. Irrespective of the tissue- and disease phase-
specific upregulation or downregulation of expression, the pathological
implication that stands from these modulations is that the histaminer-
gic system is extensively deregulated in ALS. Interestingly, the over-
whelming majority of HA-related genes that emerged as deregulated
in SOD1-G93A mice were also found to be deregulated in at least one
of sALS patient subgroups (e.g., HRH1 and HNMT), thus offering a ratio-
nale for the selection and prioritization of HA genes as potential bio-
markers and targets for patient-oriented ALS care (Apolloni et al., 2019).
Recently, a large-scale meta-analysis of genome-wide association
studies conducted on 850 patients with sALS within the Chinese popu-
lation has identified that patients carrying the Ile105 polymorphism on
the Thr105Ile allele in the HNMT gene (causing an approximately 60%
decrease in HA-degrading enzymatic activity) exhibited a trend toward
a delay in symptom onset of approximately three years. This strongly
suggests that the Thr105Ile allele in the HNMT gene could potentially
be an important therapeutic target and protectivemodifier for the treat-
ment of ALS (Chen, Kankel, Su, Han, & Ofengeim, 2018). The consequentne beyond its effects on allergy: Potential therapeutic benefits for the
.1016/j.pharmthera.2019.06.006
Fig. 1.Histamine targetsmotor neurons, glial cells, and skeletalmuscles in ALS. Schematic representation of themultitarget effects of histaminemainly acting onmotor neurons,microglia,
and skeletalmuscles, all ofwhich express histamine receptors (HR) and enzymes (HDC,HNMT, andDAO1). Inmotor neurons, histamine activates AKT and ERK1/2 pathways and increases
mitochondrial functionality and ATP content, while reducing cell death. Inmicroglia, histamine decreases the pro-inflammatorymarkers NF-κB, NADPH oxidase 2 (NOX2), and inducible
nitric oxide synthase (iNOS) and increases the anti-inflammatory mediators CD206, CD163, arginase1 (ARG1), and interleukin-10 (IL-10), while promoting cell migration. Finally,
histamine reduces myelin basic protein (MBP) loss in spinal cord and decreases muscle atrophy and neuromuscular junction (NMJ) denervation. An increased histaminergic signaling
after disease onset induces beneficial effects in ALS models.
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in patients with ALS by increasing the systemic levels of HA.
To provide a more comprehensive understanding of the HA-related
molecular mechanism, further studies have incorporated a multi-
omics approach integrating transcriptomic and genomic data with the
ALS-linked pathogenic variants from the ALSdb database, thus combin-
ing gene expression profiles, copy number variants, and single nucleo-
tide polymorphisms of patients with ALS for capturing HA pathway
associations in ALS (Apolloni et al., 2019). Numerous pathological vari-
ants are identified in the genes coding for HA receptors and enzymes. In
particular, a genome-wide analysis of multiple genomic aberrations oc-
curring in patients with sALS has identified some HA-related genes thatTable 2
Protein expression of histamine receptors and enzymes in CNS tissues from SOD1-G93A
mice during the course of disease.
Target Presymptomatic Symptomatic End stage
Cortex Cortex Cortex
H1R = ↑ ↑↑
H2R = ↓↓ =
H3R = = =
H4R ↑ = =
HDC = ↑↑ =
HNMT = ↑ =
DAO = = =
Spinal cord Spinal cord Spinal cord
H1R ↓↓ ↓ =
H2R = = ↓↓
H3R ↓↓ = =
H4R = ↑↑ =
HDC ↓↓ = ↑↑
HNMT = ↑↑ =
DAO = ↑↑ ↑
Protein expression data from cortex and spinal cord of SOD1-G93A mice at different dis-
ease stages are shown as fold change values with regard to wild type (Apolloni et al.,
2019); (Apolloni et al., 2017). One arrow: 0 b valueb2; Two arrows: 2 ≤ value≤4.
Please cite this article as: C. Volonté, S. Apolloni and M. Sabatelli, Histami
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while H3R shows duplication) and that also show a positive correlation
with transcriptomic changes in one or both sALS patient subgroups.
Among these genes, there are, for instance, genes encoding ADCYAP1,
CCKBR, and H3R (Table 4). Moreover, single nucleotide polymorphisms
are identified inH1R,H2R,H3R,H4R, HDC, HNMT, andDAOgenes. Over-
all, these results demonstrate that there is a clear homogeneity between
the HA-related genes driven by gene expression data, CNV, and SNP,
supporting the hypothesis that HA-related genes are candidate driver
genes in ALS etiopathogenesis and furthermore establishing that HA is
a gene modifier in ALS and a potential therapeutic target.Table 3



















Transcription data of histamine-related genes in post-mortem cortex and spinal cord of
sporadic ALS patient subgroups are indicated as fold change values with regard to those
of healthy individuals (Apolloni et al., 2019); (Apolloni et al., 2017). One arrow: 0
b valueb2; Two arrows: 2 ≤ value≤4.
ne beyond its effects on allergy: Potential therapeutic benefits for the
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Table 4
Genetic and transcription variations of main histamine-related genes in sporadic ALS
patients.
Target CNV SNP Transcripts
H1R \\ ✓ ✓
H2R ✓ ✓ \\
H3R ✓ ✓ ✓
H4R \\ ✓ \\
HDC \\ ✓ \\
HNMT \\ ✓ ✓
DAO ✓ ✓ \\
ADCYAP1 ✓ ✓ ✓
CCKBR ✓ \\ ✓
Data are reported from Apolloni et al. (2019). CNV: copy number variations, SNP: single
nucleotide polymorphisms. Transcript data are reported from autoptic spinal cord tissue.
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The contribution of inflammation to neurodegenerative diseases is
increasingly recognized, but the role of inflammation in ALS is not to-
tally understood. In ALS spinal cord and cortex, inflammation is
sustained by innate immune responsesmediated by inflammatorymac-
rophages/microglia and mast cells and, moreover by adaptive immune
responses sustained by T cells. ALS spinal cord presents dense macro-
phage infiltration involving bothwhite and graymatter, with the heavi-
est infiltration at lateral and ventral columns. Abundant macrophages
surround and phagocytize neurons that appear to be dying in the gray
matter. ALS spinal cords are also sparsely infiltrated with HA-releasing
mast cells (Graves et al., 2004). A recent report has shown that
degranulating mast cells are also abundant in the autopsied quadriceps
muscles from patients with ALS but not in healthy individuals. Further,
mast cells and neutrophils (producing and releasing HA) are found as-
sociatedwithmyofibers andmotor endplates and are particularly abun-
dant around motor axons in the extensor digitorum longus muscle,
sciatic nerve, and ventral roots of spinal nerves in symptomatic SOD1-
G93A rats, indicating that immune-macrophage-microglia-mast cell in-
filtration extends along the entire peripheral motor pathway in ALS
(Trias et al., 2017; Trias et al., 2018).
Activation of microglia is a complex event that can induce a gradual
conversion into numerous different phenotypes, each resembling a
specific inflammatory state. During ALS pathogenesis, microglial cells
proliferate and switch their phenotype from the protective anti-
inflammatory type to the neurotoxic pro-inflammatory type. By
confirming results that are already reported in naïve cells (Ferreira
et al., 2012), in SOD1-G93A microglia, HA directly affects cell migration
in vitro (Apolloni et al., 2017). Moreover, HA transiently activates the
MAPK pathway and stimulates anti-inflammatory mediators such as
interleukin-6, interleukin-10, arginase 1, CD163, CD206, and purinergic
P2Y12 receptor. In parallel, HA reduces pro-inflammatory pNF-κB and
NADPH oxidase 2 (Apolloni et al., 2017). Thus, HA seems very effective
in reverting the pro-inflammatory phenotype of SOD1-G93A microglia
while boosting its anti-inflammatory capacity, as thoroughly described
in other neurodegenerative conditions (W. Hu & Chen, 2017). On the
other hand, analysis in nontransgenic naïve microglia confirms that
HA stimulates a pro-inflammatory phenotype (Apolloni et al., 2017),
in line with what was previously established (Dong et al., 2014;
Ferreira et al., 2012; Frick et al., 2016; Rocha et al., 2016; Rocha, Pires,
Esteves, Graça, & Bernardino, 2014). This reinforces the notion that
the inflammatory context of the environment is fundamental for driving
the microglia response to HA (Barata-Antunes et al., 2017).
Remarkably, this is demonstrated in part also in vivo, after an acute
single injection of the brain-penetrant HA precursor histidine in
SOD1-G93A mice at the symptomatic phase of the disease, that is,
within an overt inflammatory context. A potentiated HA transmission
sustained by histidine indeed increases the protein expression of anti-
inflammatory arginase 1; further, it decreases the number of Iba1- and
CD68-positive microglia/macrophages and the pro-inflammatoryPlease cite this article as: C. Volonté, S. Apolloni and M. Sabatelli, Histami
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(Apolloni et al., 2017). Most strikingly, chronic administrations of scal-
ing doses of histidine to SOD1-G93A mice from the insurgence of the
first symptoms until the end stage of the disease produce overall bene-
ficial effects. In particular, histidine ameliorates behavioral features of
ALS, delays disease progression, improves motor performance, in-
creases life span, attenuates motor neuron loss and neuroinflammation
in the spinal cord, and finally improves neuromuscular junction integ-
rity and muscle atrophy (Apolloni et al., 2019). This confirms that histi-
dine/HA acts not only as a peripheral immunomodulatory transmitter
but also as a central neuroprotective agent. Of note, these results are
in accordance with data showing that HA protects skeletal muscles
against exercise-induced fatigue (Niijima-Yaoita et al., 2012), and HA
therapy increases tetanic forces of myoblasts, reduces muscle injury,
and improves motor performance in Duchenne muscular dystrophy in
mice (Gurel et al., 2015).
The fact that histaminergic molecules might possess a broad bioac-
tivity in ALSmodels was in part anticipated by previous results. Chronic
administration of a brain-penetrant antihistamine compound with
well-known immune-modulating properties, clemastine, in fact slightly
delayed disease progression and mildly extended survival of SOD1-
G93A mice but when administered only before the insurgence of the
first symptoms and up to the early symptomatic phase (i.e., from post-
natal day 40 to postnatal day 120). Under these conditions, clemastine
induces a strong anti-inflammatory phenotype in the spinal cord, re-
duces SOD1 aggregates, and modulates autophagy, thus suggesting
that modulation of autophagy could be indeed a promising therapeutic
strategy in ALS (Apolloni, Fabbrizio, Amadio, & Volonté, 2016). More-
over, low clemastine doses enhancemotor neuron survival and increase
anti-inflammatory Arginase-1 protein and BDNF mRNA expression,
while inhibiting the protein levels of CD68, P2X7R, phospho-ERK1/2,
and the NADPH oxidase 2 in the lumbar spinal cord of SOD1-G93A
mice at the end stage of the disease (Apolloni, Fabbrizio, Parisi,
Amadio, & Volonté, 2016). These studies suggest that some beneficial
actions of clemastine are demonstrated only in the presymptomatic/
early symptomatic phase. This confirms a critical and very narrowwin-
dow of efficacy for the use of histaminergic compounds in ALS
(Coughlan, Mitchem, Hogg, & Prehn, 2015) as previously demonstrated
also in the partial sciatic nerve ligation model of neuropathic pain (Yu
et al., 2016). Without doubt, the clemastine therapeutic regimen highly
restrains the potential clinical testing of such drugs. Conversely, the
more durable and robust beneficial effects gained by the histaminergic
treatment during the symptomatic phase of the disease surely establish
a broader translational impact of HA signaling in ALS, also confirming
the existence of an optimum lag for histaminergic drug delivery.
By discussing the extent of the histaminergic modulation in ALS
within distinct timeframes and biological actions, evidence stands that
both HA and anti-HA strategies do interfere with ALS pathogenesis.
This confirms the dual role played byHA compounds that generally pos-
sess beneficial properties within a pathologic environment (during dis-
ease progression) but that elicit detrimental actions within a
physiological milieu (before symptom onset). Indeed, during the
symptomatic phase of ALS, when disease progression accelerates in
SOD1-G93A mice in the presence of M1-like detrimental inflammatory
microglia, HA becomes anti-inflammatory and neuroprotective and it
improves pathology and survival of ALS mice. Conversely, under pre-
symptomatic conditions exhibiting M2-like microglia functions
that are beneficial for motor neurons, an anti-histaminergic therapy
seems to work, although to a lesser extent. This histaminergic/anti-
histaminergic dichotomy might be easily explained by HA drugs acting
on molecular and cellular paradigms that possess dual roles in the dis-
ease. Of note, this mirrors a dichotomy previously demonstrated, for in-
stance, in ALS microglia, acting either beneficially to prevent disease
progression at early stages or detrimentally to support disease progres-
sion through the spinal cord at later stages. A similar dualism is overall
generalized in ALS, if we look for instance at early protective T2 immunene beyond its effects on allergy: Potential therapeutic benefits for the
.1016/j.pharmthera.2019.06.006
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the stage-specific neuroimmunological response induced by NF-κB acti-
vation in astrocytes (Ouali Alami et al., 2018), at the early stimulation or
late inhibition of the inflammatory purinergic P2X7 receptor (Apolloni
et al., 2013; Apolloni et al., 2014), early or late stage autophagy (Yuan,
Zhang, & Li, 2017), and early cortical hyperexcitability and late
hypoexcitability (Geevasinga, Menon, Özdinler, Kiernan, & Vucic,
2016; Martínez-Silva et al., 2018).
Irrespective of the use of histaminergic versus antihistaminergic
compounds, the possibility of elucidating the time gap over which a
pharmacological strategy might be successful is crucial for understand-
ing the timeframe over which motor neuron degeneration can be
prevented. It is still debated if ALS begins suddenlywithin a background
of a healthy nervous system, with drastic loss of motor neurons and
emergence of progressive weakness or, instead, with slow attrition of
motor neurons and compensatory mechanisms temporarily delaying
symptoms and irreversibly evolving, once the degenerative process
overcomes the compensatory mechanisms. What is surely undeniable
is that ALS remains a challenging mission because of the complexity of
its genetic architecture, the aggravating incidence of environmental fac-
tors, and the multifactorial nature of its biological and molecular
mechanisms.
Single modality of the “one-molecule-one-target” strategy for
treating ALS has failed thus far, and future therapies on the “combina-
tion-drugs-multi-targets” approach will need to address multiple as-
pects to halt the progression of the disease. Recent works indeed
outline a transformative approach for studying and treating complex
and heterogeneous diseases such as ALS, and the last years have seen
important steps toward the development of viable diagnostic and prog-
nostic markers for ALS progression (Taga & Maragakis, 2018). Under
this perspective, this review provides a new understanding of HA-
related molecular mechanisms that might contribute to the disease.
Overall, we have disclosed a novel important role for HA in the charac-
terization of the complex multi-gene network and molecular pathways
responsible for ALS and demonstrated a favorable treatment logistic and
potential translational impact of HA in the development of more effec-
tive therapeutics. Supported by recent experimental evidence, we
have also proposed that HA might be a gene modifier of the disease,
thus establishing a novel mean for affecting ALS variability. By stimulat-
ing a further assessment of HA drugs,we hope to provide a new insight-
ful approach to the research on ALS and to open a new window for ALS
clinical trials. The indication that HA might be comprised within the
multidrug strategies or broad-spectrummolecules to be adopted to un-
derstand and alleviate ALS is certainly intriguing and encouraging.
5. Concluding remarks
The incidence of ALS globally and the number of cases will increase
from approximately 223,000 as estimated in 2015 to a projected ap-
proximate of 377,000 by 2040, representing an increase of 69%
(Arthur et al., 2016). Because this figure shows no signs of abating, pre-
dominantly due to aging of the population, especially among develop-
ing nations, one of the greatest challenges for ALS treatment is thus to
decipher the enormous complexity and heterogeneity– in origin,mech-
anism, and clinical expression – that this debilitating disease is charac-
terized by. However, ALS poses strong, sometimes daunting challenges
for understanding its mechanisms and developing effective treatments
to the point that several pharmacological approaches showing promise
against ALS have not reached sufficient efficacy and safety in vivo to sup-
port their continuation into human clinical trials.
Here we have endorsed the novel concept that histaminergic modu-
lation might work against ALS. We have referred that HA-related genes
are dysregulated in the cortex and spinal cord from patients with spo-
radic ALS, as well as in SOD1-G93A mice as a function of disease pro-
gression, and finally in ALS microglia and motor neuron cultures.
Moreover, we have reported that an integrative multi-omics approachPlease cite this article as: C. Volonté, S. Apolloni and M. Sabatelli, Histami
treatment of Amyotro..., Pharmacology & Therapeutics, https://doi.org/10combining gene expression profiles, copy number variants, and single
nucleotide polymorphisms of patients with ALS has captured HA path-
way associations in ALS, thus providing a comprehensive understanding
of HA-related molecular mechanisms that might contribute to the dis-
ease. Most importantly, we have discussed very recent works on the di-
rect anti-inflammatory and neuroprotective action of HA compounds,
not only in vitro butmost of all in vivo in SOD1-G93Amice, by highlight-
ing some durable and robust beneficial effects gained by an histaminer-
gic treatment started at the symptomatic phase of the disease.
Actually, the HA system is not new as a drug target in several animal
models of diseases and proposed to display a clear value for a wide
range of clinical conditions in the CNS (for a comprehensive review,
consult Hu & Chen, 2017). HA drugs display beneficial effects in animal
models of Parkinson's disease, dementia, and depression and are al-
ready in clinical trials for Alzheimer's disease, drug abuse, sleep disor-
ders, and relapsing-remitting multiple sclerosis. In particular, one of
the most examined H3R ligands, pitolisant (Wakix®) (Schwartz,
2011), is currently in Phase-III clinical trials for drug abuse and sleepdis-
orders and is approved by the European Medicines Agency for narco-
lepsy (Romigi, Vitrani, Lo Giudice, Centonze, & Franco, 2018).
Although we are aware that much has still to be learned about the
therapeutic strategies possibly halting or treating ALS, in this review,
an attempt has been made to challenge the histaminergic signaling as
a candidate mechanism in the disease. We trust that HAwill contribute
to expand our knowledge about ALS and that a valuable HA therapywill
be further verified in ALS. Because of its pleiotropic function, we esti-
mate that the future of HA research is still unpredictable but without
doubt exciting. HA looks far beyond to effecting just allergy, it might
be that broad-spectrum compound deserving a renewed and far-
reaching momentum in ALS.
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